BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Global Corp. (“ATGC”) today announced that it has launched the roadshow for its proposed initial public offering of 14,800,000 shares of its common stock (“Common Stock”) in the U.S. (the “Offering”). All shares […]
Tag: Anteris Technology
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
VClip™ restores mitral valve function and overcomes limitations of current technologies July 01, 2024 05:30 AM Eastern Daylight Time BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVR […]
Anteris Provides Update on DurAVR™ THV Valve-in-Valve Experience Presented at New York Valves 2024
DurAVR ViV restores similar aortic valve gradients to initial post-surgical results June 13, 2024 06:00 AM Eastern Daylight Time BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of […]
Anteris Provides Data Update on First in Human Study of DurAVR™ THV Presented at New York Valves 2024
BRISBANE, Australia & MINNEAPOLIS–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of TAVI and the world’s only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, today announced […]
Anteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve Procedure
BRISBANE, Australia & MINNEAPOLIS–(BUSINESS WIRE)–Anteris Technologies Ltd, (Anteris or the Company) (ASX: AVR), a structural heart company developing DurAVR™ THV, a new class of biomimetic heart valve and the world’s only balloon-expandable, single-piece transcatheter aortic valve shaped to mimic the performance […]
Anteris Technologies Receives FDA Clearance to Initiate Early Feasibility Study for its Novel TAVR Product, DurAVR™
U.S. Clinical Trial Commencement Anticipated in 1Q2023 BRISBANE, Australia & EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a structural heart company developing DurAVR™, the world’s only balloon-expandable, 3D single-piece aortic valve shaped to mimic the native human valve, today announced […]